Literature DB >> 7569767

Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease.

A A Van Bodegraven1, H A Tuynman, M Schoorl, A M Kruishoop, P C Bartels.   

Abstract

BACKGROUND: Factor XIII (F XIII), the last coagulation factor in the clotting cascade, plays a role in mucosal repair. Beneficial effects of F XIII supplementation in severe ulcerative colitis (UC) have been observed. The aim of this study was to relate plasma F XIII activity to the severity of inflammatory bowel disease (IBD).
METHODS: A transversional and, in part, longitudinal study of F XIII activity and related clotting products was performed in 39 patients with UC, 31 patients with Crohn's disease (CD), and 20 controls. Disease activity was assessed with a combined activity score in UC and with the Dutch Activity Index in CD.
RESULTS: F XIII activity was decreased in active UC (p < 0.05) and active CD (p < 0.05) and was inversely correlated with severity in both UC (r = -0.30) and CD (r = -0.46). In six patients with UC (15%) and six patients with CD (19%) F XIII activity was below the lower range of normal. In these patients apparent rectal bleeding was only found in severe UC. Hyperfibrinolysis was indicated by elevated levels of D-dimer (p < 0.001) notwithstanding increased concentrations of alpha-2 antiplasmin (p < 0.05).
CONCLUSIONS: In active IBD we found decreased plasma F XIII activity and hyperfibrinolysis. Decreased F XIII activity was not associated with apparent rectal bleeding in IBD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7569767     DOI: 10.3109/00365529509089793

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.

Authors:  R K Linskens; A A van Bodegraven; M Schoorl; H A Tuynman; P Bartels
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 2.  Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability.

Authors:  Danuta Owczarek; Dorota Cibor; Mikołaj K Głowacki; Tomasz Rodacki; Tomasz Mach
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Budd-Chiari syndrome in a patient with ulcerative colitis and no inherited coagulopathy.

Authors:  Sunil Dacha; Manjari Devidi; Evan Osmundson
Journal:  World J Hepatol       Date:  2011-06-27

4.  Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies.

Authors:  S Saibeni; M Vecchi; C Valsecchi; E M Faioni; C Razzari; R de Franchis
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  The microvascular thrombi of colonic tissue in ulcerative colitis.

Authors:  Guobin He; Qin Ouyang; Daiyun Chen; Fengyuan Li; Jingguo Zhou
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

Review 6.  The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.

Authors:  Christian Kleber; Armin Sablotzki; Sebastian Casu; Martin Olivieri; Kai-Martin Thoms; Johannes Horter; Felix C F Schmitt; Ingvild Birschmann; Dietmar Fries; Marc Maegele; Herbert Schöchl; Michaela Wilhelmi
Journal:  Crit Care       Date:  2022-03-24       Impact factor: 19.334

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.